Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100765 | 0.78 | HPGDS (0.46) | HPGDSLTA4HBRD4 | |
| SCHEMBL17701187 | 0.67 | HPGDS (0.37) | HPGDSLTA4H | |
| SCHEMBL1429347 | 0.65 | HPGDS (0.33) | HPGDSLTA4H | |
| SCHEMBL9455041 | 0.65 | HPGDS (0.35) | HPGDSLTA4HBRD4 | |
| SCHEMBL17701183 | 0.64 | HPGDS (0.39) | HPGDSLTA4HBRD4 | |
| SCHEMBL17701242 | 0.64 | HPGDS (0.35) | HPGDSLTA4H | |
| SCHEMBL722557 | 0.64 | LTA4H (0.64) | HPGDSLTA4HBRD4 | |
| SCHEMBL5820537 | 0.64 | HPGDS (0.34) | HPGDSLTA4H | |
| SCHEMBL221943 | 0.63 | HPGDS (0.33) | HPGDSLTA4H | |
| SCHEMBL6819807 | 0.63 | HPGDS (0.33) | HPGDSLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9700563-B2 | Kappa opioid receptor compounds | MediSynergies, LLC (US) | 2017-07-11 | — | — | US | claimed |
| EP-3843731-A1 | METHODS OF TREATING HYPERSENSITIVE COUGH OR ITCHING USING ION CHANNEL INHIBITORY COMPOUNDS | Afasci, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-112236424-A | Alkoxy-substituted pyridyl derivatives | 爱杜西亚药品有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2020047168-A1 | METHODS OF TREATING HYPERSENSITIVE COUGH OR ITCHING USING ION CHANNEL INHIBITORY COMPOUNDS | AFASCI, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| EP-2592073-A2 | Human protein tyrosine phosphatase inhibitors and their use | Warner Chilcott Company, LLC (PR) | 2013-05-15 | — | — | EP | disclosed |
| US-7238716-B2 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-0605228-A1 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1994-07-06 | — | — | EP | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0318860-B1 | SUBSTITUTED ALKYLAMINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | GPR119, ACOX1, ALK | HPGDS 1763/4885LTA4H 282/4885BRD4 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.